Table 1.
General characteristic of the included studies.
| First Author | publication year | study design | types of ARDs | disease duration (mean ± SD) | number | age (mean ± SD) | sex (M/F) | NOS scale | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Patint | Control | Patient | Control | Patient | Control | ||||||
| A. Balkarl | 2016 | retrospective study | BD | N | 120 | 79 | 37.83 ± 11.86 | 37.63 ± 10.82 | 72/48 | 46/33 | 8 |
| Acikgoz, N. | 2010 | retrospective study | BD | 9.1 ± 5.1 | 60 | 40 | 40.5 ± 12.9 | 41.3 ± 6.8 | 31/29 | 18/22 | 8 |
| Boyraz, I. | 2014 | retrospective study | AS | N | 105 | 50 | 46.83 ± 14.94 | 41.02 ± 17.37 | 78/27 | 28/22 | 8 |
| Boyraz, I. | 2016 | retrospective study | AS | 8.8 ± 8 | 30 | 25 | 38.6 ± 8.3 | 37.1 ± 9.4 | 19/11 | 16/9 | 8 |
| Bozan, N. | 2016 | retrospective study | AS | 5.29 ± 5.09 | 30 | 35 | 32 ± 8 | 32 ± 6 | 18/12 | 22/13 | 7 |
| Coskun, B. N. | 2014 | retrospective study | AS | 9.25 ± 8.37 | 35 | 38 | 38.91 ± 11.90 | 37.36 ± 6.90 | 26/9 | 26/12 | 8 |
| Gokmen, F. | 2015 | retrospective study | AS | N | 96 | 81 | 43.8 ± 12.9 | 46.5 ± 11.2 | 65/31 | 47/34 | 6 |
| Li, L. | 2015 | retrospective study | SLE | N | 59 | 149 | 29.47 ± 12.63 | 28.44 ± 4.42 | 4/55 | 17/132 | 8 |
| Mercan, R. | 2016 | retrospective study | AS | N | 140 | 117 | 37.1 ± 9.8 | 37.2 ± 13.2 | 79/61 | 42/75 | 8 |
| RA | N | 136 | 117 | 51.7 ± 13.5 | 37.2 ± 13.2 | 15/121 | 42/75 | ||||
| Oehadian, A. | 2013 | cross sectional study | SLE | N | 21 | 30 | 28.5 ± 41.08 | 28.5 ± 60.42 | 0/21 | 10/20 | 8 |
| Ozturk, C. | 2015 | retrospective study | BD | 9.26 ± 7.09 | 65 | 62 | 36.30 ± 10.98 | 34.16 ± 9.33 | 38/27 | 31/31 | 8 |
| Peng, Y. F. | 2014 | retrospective study | AS | N | 44 | 113 | 35.98 ± 16.24 | 33.87 ± 7.88 | 30/14 | 82/31 | 8 |
| Rifaioglu, E. N. | 2014 | retrospective study | BD | N | 65 | 136 | 37.7 ± 12.3 | 38.8 ± 11.3 | 38/17 | 56/80 | 8 |
| Safak, S. | 2014 | retrospective study | SLE | N | 44 | 44 | 42 ± 16 | 41 ± 17 | 11/33 | 9/35 | 8 |
| Soydinc, S. | 2014 | retrospective study | SSc | N | 76 | 45 | 50.44 ± 13.21 | 46.52 ± 13.16 | 14/62 | 11/34 | 8 |
| Wu, Y. | 2016 | retrospective study | SLE | N | 116 | 136 | 27.81 ± 32.73 | 28.5 ± 12.75 | 19/97 | 25/111 | 8 |
| Yolbas, S. | 2016 | retrospective study | BD | 6.9 ± 5.9 | 53 | 55 | 37.4 ± 10.9 | 45.1 ± 13 | 20/33 | 11/44 | 8 |
| RA | 8.2 ± 7.9 | 91 | 55 | 51.7 ± 14.5 | 45.1 ± 13 | 15/76 | 11/44 | ||||
| SLE | 4.6 ± 5.2 | 51 | 55 | 33 ± 9.6 | 45.1 ± 13 | 4/47 | 11/44 | ||||
| Zengin, O. | 2016 | retrospective study | RA | N | 317 | 104 | 44.33 ± 10.41 | 43.16 ± 11.69 | 206/111 | 68/36 | 7 |
F: female; M: male; RA: rheumatoid arthritis; SLE: systemic lupus erythematosus; BD: Behçet’s Disease; AS: ankylosing spongdylitis; SD: standard deviation; NOS: Newcastle-Ottawa scale.